HELP Study ExtensionTM: An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of DX-2930 for Prevention Against Acute Attacks of Hereditary Angioedema (HAE)

ID Number 16-2472

Principal Investigator(s)
Paula J Busse

Department(s) or Division(s)
Clinical Immunology


The purpose of this research study is to:

  • Test the long-term safety of DX-2930
  • Evaluate if DX-2930 can prevent HAE attacks
  • To evaluate how often DX-2930 should be given
  • Test participants' blood to see how DX-2930 affects them
  • Help understand if DX-2930 affects their day-to-day life
  • To evaluate their experience if they choose to self-administer DX-2930

The test medicine being studied is called DX-2930.  DX-2930 is a ‘monoclonal antibody’ – these are man made versions of the proteins (antibodies) that the immune system makes to attach to specific targets in the body. DX-2930 blocks an enzyme called plasma kallikrein. This test medicine is undergoing research to see if it can prevent HAE attacks and if it is safe or not.

Contact Information
Olia Ali
(212) 241-1617

Recruiting Patients: Yes